NCT07095127View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Immune Thrombocytopenia (ITP)
Interventions
DRUG

NVG-2089

Study Treatment

Trial Locations (1)

11590

RECRUITING

Nuvig Site, Westbury

Sponsors
All Listed Sponsors
lead

Nuvig Therapeutics, Inc.

INDUSTRY